MHC-I loss or downregulation in cancer cells is a major mechanism of resistance to T cell–based
immunotherapies. Our study reveals that birinapant may be used for patients with low …

γδ T cells are potent anticancer effectors with the potential to target tumours broadly, independent
of patient-specific neoantigens or human leukocyte antigen background 1 , 2 , 3 , 4 – 5 …

Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited efficacy
of single agents. The design and testing of combinations are however very challenging. …

Background Acute myeloid leukemia (AML), caused by the abnormal proliferation of
immature myeloid cells in the blood or bone marrow, is one of the most common hematologic …

The phenotypic effect of perturbing a gene's activity depends on the activity level of other
genes, reflecting the notion that phenotypes are emergent properties of a network of …

Background Immune checkpoint blockade (ICB) therapy has improved patient survival in a
variety of cancers, but only a minority of cancer patients respond. Multiple studies have …

The advent of high-throughput technologies such as ChIP-seq has made possible the study
of histone modifications. A problem of particular interest is the identification of regions of the …

Most patients with advanced cancer eventually acquire resistance to targeted therapies,
spurring extensive efforts to identify molecular events mediating therapy resistance. Many of …

Background Predictive biomarkers of immune checkpoint inhibitor (ICI) efficacy are currently
lacking for non-small cell lung cancer (NSCLC). Here, we describe the results from the Anti–…

Background In cell differentiation, a cell of a less specialized type becomes one of a more
specialized type, even though all cells have the same genome. Transcription factors and …